Guggenheim Assumes CRISPR Therapeutics at Neutral
CRISPR Therapeutics AG +4.96% Pre
CRISPR Therapeutics AG CRSP | 49.71 49.71 | +4.96% 0.00% Pre |
Guggenheim analyst Debjit Chattopadhyay assumes CRISPR Therapeutics (NASDAQ:
CRSP) with a Neutral rating.